Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Patel, P. H.
Kondagunta, G. V.
Redman, B. G.
Hudes, G. R.
Kim, S. T.
Chen, I.
Motzer, R. J.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] Pfizer Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5097
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PHASE II MULTICENTRIC STUDY OF SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (MRCC) WITH A POOR PROGNOSIS REFRACTORY TO IMMUNOTHERAPY
    Longo, N.
    Di Lorenzo, G.
    Fusco, F.
    Verze, P.
    Barba, C.
    Arcaniolo, D.
    Mirone, V
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 183 - 183
  • [42] Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma (mRCC): A GION trial.
    Porta, Camillo
    Ferrari, Vittorio D.
    Zucali, Paolo Andrea
    Fornarini, Giuseppe
    Bernardo, Antonio
    Falconeri, Andrea
    Ferrari, Alessandra
    Santarossa, Sandra
    Pappagallo, Giovanni L.
    Bearz, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results
    Tomasello, L.
    Sertoli, M. R.
    Rubagotti, A.
    Guglielmini, P.
    Tacchini, L.
    Bedognetti, D.
    Ricci, F.
    Sanguineti, S.
    Cassata, A.
    Boccardo, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Sunitinib safety and tolerability in patients with metastatic renal cell carcinoma (MRCC)
    Ferrari, A.
    Sabbatini, R.
    Maur, M.
    Giovannelli, S.
    Jovic, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
  • [45] Phase II study of bortezomib and thalidomide in patients with metastatic renal cell carcinoma (MRCC).
    Amato, R
    Misellati, A
    Marsh, L
    Shen, S
    Jac, J
    Ross, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9121S - 9122S
  • [46] Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival
    Rosenberg, J. E.
    Motzer, R. J.
    Michaelson, M. D.
    Redman, B. G.
    Hudes, G. R.
    Bukowski, R. M.
    George, D. J.
    Kim, S. T.
    Baum, C. M.
    Wilding, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
    Zibelman, Matthew R.
    Geynisman, Daniel M.
    Molina, Ana M.
    Malizzia, Lois
    Devarajan, Karthik
    Luong, Diana
    Sullivan, Elizabeth
    Carducci, Michael Anthony
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Phase II study of CC-5013 in patients (pts) with metastatic renal cell cancer (MRCC)
    Rawat, A
    Needle, MN
    Miles, B
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 403S - 403S
  • [49] Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib
    Golshayan, A. R.
    Elson, P.
    Wood, L. S.
    Garcia, J. A.
    Dreicer, R.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus
    Salas, R. N.
    Ireland, J. L.
    Ko, J. S.
    Elson, P.
    Garcia, J. A.
    Wood, L.
    Bukowski, R. M.
    Rini, B. I.
    Finke, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345